
    
      This is a randomized, double-blind, placebo-controlled study of NP001 in subjects with ALS
      and evidence of elevated systemic inflammation. Subjects will be allocated (1:1) to NP001 and
      placebo. Drug or placebo will be given intravenously.
    
  